The Uppsala Monitoring Centre produces the family of WHO Drug Dictionaries, which are used by more than 1,000 pharmaceutical companies, CROs and regulatory bodies every day.

The Uppsala Monitoring Centre (UMC) offers medical terminologies and analytical services for the international community of pharma, biotech and CRO companies, academia and software developers. If clinical trials or drug safety operations are your business, it has the tools and resources to support your work and enhance your productivity.

Today, more than 1,000 pharmaceutical companies, CROs and regulatory bodies around the world use UMC’s WHO Drug Dictionaries in their day-to-day activities. Common examples of this usage include the coding, analysis and reporting of concomitant medications found in clinical trials, as well as for drug names appearing on individual case safety reports (ICSRs).

UMC, the WHO Collaborating Centre for International Drug Monitoring, has been at the heart of international medicinal safety since its formation in 1978 in Uppsala, Sweden. Its database of more than seven million adverse reaction reports is the largest collection of drug safety information anywhere. The centre is a non-profit foundation, its priorities being the safety of patients, and the safe and effective use of medicines in every part of the world. It meets these priorities through innovative research and development, and by providing data, reference, consultative and training resources to medicines regulatory agencies, health professionals, researchers and the pharmaceutical industry all over the world.

An expanding family of drug dictionaries

UMC’s WHO Drug Dictionaries and related services optimise the global coding, analysis and reporting of medical product information from clinical trials and within drug safety. WHO Drug Dictionary Enhanced (WHO DDE) is the world’s most comprehensive and widely applied drug coding reference. It is also the central point of an expanding family of related drug dictionaries and services, all seamlessly connected using the same working methods and terminologies. UMC drug dictionaries use the hierarchical system for anatomical therapeutic chemical classes (ATCs), promoting aggregation of statistics in analysis and reporting.


WHO DDE’s hierarchical product coding system, its range of powerful analytical tools and its extensive global coverage make it a valued means of interpreting and reporting medicinal product information. Most importantly, WHO DDE meets the expressed need for a consistent drug dictionary and exact terminology. With WHO DDE, users are able to code concomitant medication, better analyse and understand the resulting data, and accelerate submissions to regulatory authorities. Drug safety surveillance is also enhanced.

WHO Herbal Dictionary

With its unique herbal anatomical therapeutic chemical (H-ATC) classification, WHO Herbal Dictionary (WHO HD) helps the industry and regulators more fully understand herbal concomitant medications used by patients. Containing herbal drugs from all over the world, it allows for herbal drug names to be translated into information used to code and analyse drug safety data.

Cross Reference Tool Japan

Cross Reference Tool Japan (CRT Japan) directly matches Iyakuhinmei data file (IDF) codes with WHO DDE codes. IDF is Japan’s national dictionary for reporting drug safety data to the PMDA (the Japanese drug agency). CRT Japan offers pharmaceutical companies and CROs active in Japan a simple solution for coding and submitting concomitant medications to the PMDA.

Drug Dictionary China

Drug Dictionary China (DDC) translates Chinese-character medicinal product names into the WHO DDE coding system. This simple conversion gives users access to a broad array of up-to-date medicinal product information for products used on the Chinese market, including herbal medicines and traditional Chinese medicines (TCMs).

Standardised drug groupings

Standardised drug groupings (SDGs) simplify the creation of ‘medications of interest’ and protocol violation lists. These lists can be used, for example, when identifying possible drug-drug interactions. All UMC SDGs are prioritised by the user community, developed by pharmaceutical experts and peer-reviewed by counterparts in related fields.